Welcome to AiCuris: The Powerhouse for Anti-Infectives
| AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. | Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success. |
AiCuris-Team receives German Future Prize / AiCuris-Team mit dem Deutschen Zukunftspreis ausgezeichnet
Cooperation with Cyclenium
AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.
AIC649 Positive Phase 1 Hepatitis B
AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B
- Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
- The trial provides evidence that AIC649 stimulates the immune system of chronic hepatitis B patients
- Further trials to study the potential of AIC649 to induce a functional cure in chronic hepatitis B virus (HBV)-infection is warranted
Job Opportunities
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.